Adjuvant testing pipeline for recombinant SARS-CoV2 vaccines

NIH RePORTER · NIH · N01 · $1,790,282 · view on reporter.nih.gov ↗

Abstract

To identify the optimal adjuvant for recombinant SARS-CoV2 vaccines for vaccine recipients of different ages, and to identify correlates of protection against SARS-CoV2 infection or disease, experimental SARS-CoV2 vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

Key facts

NIH application ID: 10301484
Project number: 75N93019C00044-P00002-9999-2
Recipient: BOSTON CHILDREN'S HOSPITAL
Principal Investigator: OFER LEVY
Activity code: N01
Funding institute: NIH
Fiscal year: 2020
Award amount: $1,790,282
Award type: —
Project period: 2019-09-30 → 2024-09-29